Crispr Therapeutics AG (CRSP) — Free Cash Flow Generation Index

Latest as of March 2024: 0.99x

Crispr Therapeutics AG (CRSP) has a Free Cash Flow Generation Index of 0.99x as of March 2024. Free cash flow of $109.03 Million represents 1% of operating cash flow ($109.75 Million). Read Crispr Therapeutics AG (CRSP) total liabilities for a breakdown of total debt and financial obligations.

FCF Generation Index

0.99x
Free Cash Flow / Operating CF

Free Cash Flow

$109.03 Million
USD

Operating Cash Flow

$109.75 Million
USD

Capital Expenditures

$721.00K
USD

Crispr Therapeutics AG Free Cash Flow Generation Index (2015–2021)

Historical FCF Generation Index trend for Crispr Therapeutics AG across 3 annual periods. Explore Crispr Therapeutics AG (CRSP) reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.

Annual Free Cash Flow Generation for Crispr Therapeutics AG (2015–2021)

Year-by-year Free Cash Flow Generation Index for Crispr Therapeutics AG. For the full company profile including market capitalisation, see market cap of Crispr Therapeutics AG.

Year FCG Index Free Cash Flow (USD) Operating CF Capital Expenditures YoY Change
2021 0.85x $457.27 Million $538.97 Million $81.70 Million ▼ -3.8%
2019 0.88x $49.99 Million $56.68 Million $6.68 Million ▼ -10.0%
2015 0.98x $58.27 Million $59.43 Million $1.15 Million
FCG Index = Free Cash Flow / Operating Cash Flow. FCF = Operating CF + Capital Expenditures (capex stored negative).